

## ACCESS

Immunoassay Systems

## Instructions For Use

## Access OV Monitor

## Cancer Antigen 125

**REF** 386357

### FOR PROFESSIONAL USE ONLY

Rx Only

### ANNUAL REVIEW

Reviewed by	Date	Reviewed by	Date

### PRINCIPLE

#### WARNING

The concentration of CA 125 antigen in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods and reagent specificity. The results reported by the laboratory to the physician must include the identity of the CA 125 antigen assay used. Values obtained with different assay methods cannot be used interchangeably. If, in the course of monitoring a patient, the assay method used for determining CA 125 antigen values is changed, additional sequential testing should be carried out to confirm baseline values.

#### INTENDED USE

The Access OV Monitor assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of CA 125 antigen levels in human serum and plasma using the Access Immunoassay Systems. This device is indicated for use in the measurement of CA 125 antigen to aid in the management of ovarian cancer patients. Serial testing for patient CA 125 antigen concentrations should be used in conjunction with other clinical methods used for monitoring ovarian cancer.

#### SUMMARY AND EXPLANATION

The CA 125 antigen is an epitope on a large mucin-like glycoprotein (MW ~ 1000 kDa)<sup>1</sup> that may be found in elevated concentrations in certain ovarian malignancies. There is no known function for CA 125.

Ovarian cancer is one of the most common types of gynecological malignancies, and the fourth most frequent cause of cancer death in women.<sup>2</sup> Ovarian cancer tends to be asymptomatic in its earliest, more curable stages, and many patients have widespread disease at the time of discovery. Some favorable prognostic factors include younger age, lower stage, well-differentiated tumor, and small disease volume prior to surgery.<sup>3</sup>

CA 125 antigen levels have no proven prognostic value when used for either screening or at time of diagnosis. However, CA 125 antigen levels do correlate with patient status after initial treatment.<sup>4,5</sup>

Serum CA 125 antigen levels may be used as an aid in monitoring the response to therapy for patients with epithelial ovarian carcinoma. The presence of persistently rising CA 125 antigen levels may be correlated with disease progression. Persistently elevated CA 125 antigen levels indicate poor response to therapy, whereas decreasing CA 125 antigen levels may indicate a positive therapeutic response.<sup>6,7,8</sup>

CA 125 antigen levels are elevated in many patients with epithelial ovarian carcinoma. It may also be elevated in diseases other than epithelial ovarian carcinoma, including other benign or malignant ovarian diseases, such as endometriosis, and in lung cancer and in other non-cancerous conditions such as pregnancy.

Historically, CA 125 antigen levels have been used in conjunction with second-look surgery, but this procedure is less commonly used today.<sup>8,9</sup> A recent NIH Consensus panel has recommended the use of serial CA 125 testing in lieu of second look surgery, at least for those women with a preoperative increase of CA 125.<sup>10,11</sup>

The Access OV Monitor assay is not recommended as a screening tool. A value below the cutoff limit does not indicate the absence of residual ovarian cancer. Other clinically acceptable tests and procedures should also be considered in the monitoring of ovarian cancer and good patient management.

Some individuals have antibodies to mouse protein (HAMA) which can cause interference in immunoassays that employ antibodies derived from mice. In particular, it has been reported that serum samples from patients who have undergone therapeutic or diagnostic procedures that include infusion of mouse monoclonal antibodies may produce erroneous results in such assays. Additionally, other heterophile antibodies may be present in patient samples. Therefore, results for such patients should be used only in conjunction with results from some other diagnostic procedures and with information available from the clinical evaluation of the patient.

## **METHODOLOGY**

The Access OV Monitor assay is a two-site immunoenzymatic (“sandwich”) assay. A sample is added to a reaction vessel along with mouse monoclonal anti-CA 125 antigen alkaline phosphatase conjugate and paramagnetic particles coated with a second mouse monoclonal anti-CA 125 antigen antibody. The CA 125 antigen in the sample binds to the immobilized monoclonal anti-CA 125 antigen on the solid phase, while the conjugate antibody reacts with a different antigenic site on the CA 125 antigen molecule.

After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of CA 125 antigen in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.

## **SPECIMEN**

### **Specimen Collection and Preparation**

1. Serum and plasma (heparin) are the recommended samples.
2. Observe the following recommendations for handling, processing, and storing blood samples:<sup>12</sup>
  - Collect all blood samples observing routine precautions for venipuncture.
  - Allow serum samples to clot completely before centrifugation.
  - Keep tubes stoppered at all times.
  - Physically separate serum or plasma from contact with cells as soon as possible.
  - Store samples tightly stoppered at room temperature (15 to 30°C) for no longer than eight hours.
  - If the assay will not be completed within eight hours, refrigerate the samples at 2 to 8°C.
  - If the assay will not be completed within 48 hours, or for shipment of samples, freeze at -20°C or colder.

- Thaw samples only once.
3. Use the following guidelines when preparing specimens:
- Ensure residual fibrin and cellular matter has been removed prior to analysis.
  - Follow blood collection tube manufacturer's recommendations for centrifugation.
4. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot.

## REAGENTS

### Product Information

#### Access OV Monitor Reagent Pack

**Cat. No. 386357: 100 determinations, 2 packs, 50 tests/pack**

- Provided ready to use.
- Store upright and refrigerate at 2 to 10°C.
- Refrigerate at 2 to 10°C for a minimum of two hours before use on the instrument.
- Stable until the expiration date stated on the label when stored at 2 to 10°C.
- Stable at 2 to 10°C for 28 days after initial use.
- Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.
- If the reagent pack is damaged (i.e., broken elastomer), discard the pack.
- All antisera are polyclonal unless otherwise indicated.

<b>R1a:</b>	Paramagnetic particles, coated with goat anti-biotin antibodies, biotinylated anti CA 125 antigen mouse monoclonal antibodies, bovine serum albumin, < 0.1% sodium azide, and 0.1% ProClin* 300.
<b>R1b:</b>	Mouse monoclonal anti-CA 125 antigen-alkaline phosphatase (bovine) conjugate, bovine serum albumin, < 0.1% sodium azide, and 0.1% ProClin 300.
<b>R1c:</b>	Buffered protein solution (bovine, goat, mouse), < 0.1% sodium azide and 0.1% ProClin 300.

\*ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.

### WARNING AND PRECAUTIONS

- For *in vitro* diagnostic use.
- Patient samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS, GHS HAZARD CLASSIFICATION and EU HAZARD CLASSIFICATION.

## REACTIVE INGREDIENTS

### CAUTION

Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.

## GHS HAZARD CLASSIFICATION

PMP (Compartment R1a)

WARNING



H317

May cause an allergic skin reaction.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Conjugate (Compartment R1b)

WARNING



H317

May cause an allergic skin reaction.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and

2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Blocking Agent  
(Compartment R1c)

WARNING



H317

May cause an allergic skin reaction.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

	Safety Data Sheet is available at <a href="http://techdocs.beckmancoulter.com">techdocs.beckmancoulter.com</a>
--	--

## EUROPEAN HAZARD CLASSIFICATION

PMP (Compartment R1a)

Xi;R43

R43

May cause sensitization by skin contact.

S28

After contact with skin, wash immediately with plenty of soap and water.

S37

Wear suitable gloves.

Conjugate (Compartment R1b)

Xi;R43

R43

May cause sensitization by skin contact.

S28

After contact with skin, wash immediately with plenty of soap and water.

S37

Wear suitable gloves.

Blocking Agent (Compartment R1c)

Xi;R43

R43

May cause sensitization by skin contact.

S28	After contact with skin, wash immediately with plenty of soap and water.
S37	Wear suitable gloves.

## MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

1. Access OV Monitor Calibrators  
Provided at zero and approximately 25, 100, 500, 2,000 and 5,000 U/mL.  
Cat. No. 386358
2. Quality Control (QC) materials: commercial control material
3. Access Sample Diluent A  
Vial Cat. No. 81908  
Diluent Pack Cat. No. A79783 (For use with the UniCel DxI system onboard dilution feature.)
4. Access Substrate  
Cat. No. 81906
5. Access Wash Buffer II, Cat. No. A16792  
UniCel DxI Wash Buffer II, Cat. No. A16793

## Equipment and Materials

R1	Access OV Monitor Reagent Packs
----	---------------------------------

## CALIBRATION

### CALIBRATION INFORMATION

An active calibration curve is required for all tests. For the Access OV Monitor assay, calibration is required every 28 days. Refer to the appropriate system manuals and/or Help system for information on calibration theory, configuring calibrators, calibrator test request entry, and reviewing calibration data.

## QUALITY CONTROL

Quality control materials simulate the characteristics of patient samples and are essential for monitoring the system performance of immunochemical assays. Because samples can be processed at any time in a "random access" format rather than a "batch" format, quality control materials should be included in each 24-hour time period.<sup>13</sup> Include commercially available quality control materials that cover at least two levels of analyte. More frequent use of controls or the use of additional controls is left to the discretion of the user, based on good laboratory practices or laboratory accreditation requirements and applicable laws. Follow manufacturer's instructions for reconstitution and storage. Each laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results that do not fall within acceptable ranges may indicate invalid test results. Examine all test results generated since obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or Help system for information about reviewing quality control results.

## TESTING PROCEDURE(S)

### PROCEDURAL COMMENTS

1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, principles of operation, system performance characteristics, operating instructions, calibration procedures,

operational limitations and precautions, hazards, maintenance, and troubleshooting.

2. Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the instrument. Do not invert open (punctured) packs.
3. Use twenty-five (25)  $\mu\text{L}$  of sample for each determination in addition to the sample container and system dead volumes. Use twenty-five (25)  $\mu\text{L}$  of sample in addition to the sample container and system dead volumes for each determination run with the DxI system onboard dilution feature. Refer to the appropriate system manuals and/or Help system for the minimum sample volume required.
4. The system default unit of measure for sample results is U/mL.

## PROCEDURE

Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests, requesting tests, and reviewing test results.

## RESULTS INTERPRETATION

Patient test results are determined automatically by the system software using a weighted four parameter logistic curve (4PLC) math model. The amount of analyte in the sample is determined from the measured light production by means of the stored calibration data. Patient test results can be reviewed using the appropriate screen. Refer to the appropriate system manuals and/or Help system for complete instructions on reviewing sample results.

## REPORTING RESULTS

### EXPECTED RESULTS

1. Each laboratory should establish its own reference ranges to assure proper representation of specific populations.
2. The distribution of Access OV Monitor results, presented below, were determined from a total of 889 serum samples from apparently healthy females and males and females with non-malignant and malignant conditions.

Subject Category	Number of Subjects	0-35 U/mL	35.1-65 U/mL	65.1-100 U/mL	> 100 U/mL
<b>Apparently Healthy</b>					
Females	170	166	3	1	0
Males	51	51	0	0	0
<b>Malignant Conditions (including previously treated patients)</b>					
Ovarian	141	94	10	6	31
Breast	48	43	3	1	1
Cervical	27	22	1	1	3
Colon	50	47	2	1	0
Endometrial	8	5	2	1	0

Subject Category	Number of Subjects	0-35 U/mL	35.1-65 U/mL	65.1-100 U/mL	> 100 U/mL
Esophageal	9	7	1	0	1
Fallopian Tube	5	3	0	1	1
Gastric/Stomach	13	7	2	2	2
Lung	50	28	9	3	10
Pancreatic	25	14	0	2	9
Uterine	26	19	1	1	5
Vaginal/Vulva	12	11	1	0	0
<b>Non-Malignant Conditions</b> (including previously treated patients)					
Ovarian	28	28	0	0	0
Colon	43	43	0	0	0
Cystitis	9	8	1	0	0
Endometriosis	22	21	0	1	0
Gastric/Stomach	39	37	1	0	1
Pelvic Inflammatory Disease	8	7	1	0	0
Uterine Fibroids	30	25	1	1	3
Pregnancy	75	42	22	4	7

## Clinical Performance in Ovarian Cancer Patients

### Relative Sensitivity and Specificity

Relative sensitivity and specificity were calculated for the Access OV Monitor vs. another automated commercially available assay. In this study sensitivity and specificity calculations were based on the 35 U/mL upper reference limit for both assays. The analyses are based on 141 samples from 141 subjects originally diagnosed with ovarian cancer (stages I to IV) and at various stages of the disease. These subjects may have undergone surgery, chemotherapy, or radiation during the course of disease management. A non-parametric Wilcoxon analysis of results demonstrate that the median CA 125 values are not statistically different between the Access OV Monitor assay and the reference CA 125 assay with p-value = 0.9557. Based on the 141 ovarian cancer subjects, the relative



sensitivity and specificity were 95.8% and 98.9%, respectively.

### Clinical Concordance (Sensitivity and Specificity)

In this study, clinical sensitivity and specificity were based on the 35 U/mL upper reference limit. Clinical sensitivity is calculated based on a total of 45 serum samples from 45 females originally diagnosed with ovarian cancer (stage II to stage IV) and who are diagnosed with disease progression at the time of sample draw date. Clinical specificity calculations are based on a total of 63 samples from 63 females originally diagnosed with ovarian cancer (stage II to stage IV) and who are diagnosed with no evidence of disease (NED) at the time of sample draw date. These subjects may have undergone surgery, chemotherapy, or radiation during the course of disease management. Based on these two populations, the clinical sensitivity and specificity, based on the 35 U/mL upper reference limit, were 84.4% and 81.0%, respectively. Disease status is based on one or more clinical diagnostic modalities. The method(s) used to determine disease status at sample draw date included: biopsy, physical exam, x-rays, exploratory laparoscopy, CAT scan, ultrasound, pelvic echogram, isotope scan, CA 125 measurements, MRI.

In addition to the above studies, serial samples with known disease status (total of 118 samples) were obtained from 20 females (ages ranging from 27 to 84 years) who were diagnosed with ovarian cancer (stages I to IV ovarian cancer). These subjects were monitored over the course of disease, ranging from 7 months to 53 months. Presented below is a summary table showing the concordance of clinical results relative to the 35 U/mL cut-off using the Access OV Monitor assay.

<b>Access OV Monitor Serial Evaluation -- # of Observations (20 Patients/118 Total Samples)</b>		
<b>Disease status at time of sample draw</b>	<b>Access OV Monitor</b>	
	<b>&lt; 35 U/mL</b>	<b>≥ 35 U/mL</b>
<b>Progression<sup>†</sup></b>	8	41
<b>Completed Remission<sup>††</sup></b>	36	7
<b>Partial Remission</b>	6	10
<b>Minimal Improvement</b>	3	7
<b>Concordance: Progression (Clinical Sensitivity)</b>	41/49 (83.7%)	
<b>Concordance: Response to therapy (NED)<sup>†††</sup> (Clinical Specificity)</b>	36/43 (83.7%)	

<sup>†</sup> Used for the Clinical Sensitivity Calculation

<sup>††</sup> Used for the Clinical Specificity Calculation

<sup>†††</sup> No evidence of disease (NED)

Of the 118 samples with known disease status information, 49 samples were classified as progression (or active disease), 43 samples as complete remission (NED), 16 samples as partial remission, and 10 samples as minimal improvement. The clinical sensitivity (based on the 49 progression samples) and the clinical specificity (based on the 43 complete remission samples) were 83.7% and 83.7%, respectively. For this ovarian cancer population, identical clinical sensitivity and clinical specificity results were obtained between the Access OV Monitor assay and the commercially available automated assay discussed in the Relative Sensitivity and Specificity section above.

## PROCEDURAL NOTES

### LIMITATIONS

1. Samples can be accurately measured within the analytic range of the lower limit of detection and the highest calibrator value (approximately 0.5 U/mL and 5,000 U/mL).
  - If a sample contains less than the lower limit of detection for the assay, report the results as less than that value (i.e., < 0.5 U/mL). When the Dxl system onboard dilution feature is used, the system will report results as less than 4,250 U/mL.
  - If a sample contains more than the stated value of the highest Access OV Monitor Calibrator (S5), report the result as greater than that value (i.e., > 5,000 U/mL). Alternatively, dilute one volume of sample with 9 or 19 volumes of Access OV Monitor Calibrator S0 (zero) or Access Sample Diluent A. Refer to the appropriate system manuals and/or Help system for instructions on entering a sample dilution in a test request. The system reports the results adjusted for the dilution. The Dxl system onboard dilution feature automates the dilution process, using one volume of sample with nineteen volumes of Access Sample Diluent A, allowing samples to be quantitated up to approximately 100,000 U/mL. The system reports the results adjusted for the dilution.
2. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may be present in patient samples.<sup>14,15</sup> Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies.
3. The Access OV Monitor results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests and other appropriate information. Serum or plasma OV Monitor concentrations should not be interpreted as absolute evidence for the presence or absence of cancer. Elevated concentrations may be observed in the serum or plasma of patients with benign conditions or other non-cancer disorders, as well as in ovarian cancer and other metastatic diseases. The Access OV Monitor assay should not be used as a cancer screening test.
4. The Access OV Monitor assay does not demonstrate any “hook” effect up to 120,000 U/mL.

## PERFORMANCE CHARACTERISTICS

### PERFORMANCE CHARACTERISTICS

#### METHODS COMPARISON

A comparison of 290 values using the Access OV Monitor assay on the Access Immunoassay system and a commercially available immunoassay system gave the following statistical data using Deming calculations:

n	Range of Observations (U/mL)	Intercept (U/mL)	Slope	Correlation Coefficient (r)
290	0-600	-1.0	1.20	0.9871

#### DILUTION RECOVERY (LINEARITY)

Multiple dilutions of 3 samples containing various CA 125 antigen levels with Access OV Monitor Calibrator S0 (zero) resulted in the following data:

Sample 1 (ID)	Dilution (U/mL)	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
A	0	2,659	2,659	100
	1:2	1,329	1,334	100.4
	1:5	532	560	105.3
	1:10	266	291	109.4
	1:100	27	30	111.1
			<b>Mean % Recovery</b>	<b>107</b>

Sample 2 (ID)	Dilution (U/mL)	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
B	0	4,277	4,277	100
	1:2	2,139	2,211	103.4
	1:5	855	938	109.7
	1:10	428	460	107.5
	1:200	21	24	114.3
			<b>Mean % Recovery</b>	<b>109</b>

Sample 3 (ID)	Dilution (U/mL)	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
C	0	2,186	2,186	100
	1:2	1,093	1,131	103.5
	1:5	437	490	112.1
	1:10	219	248	113.5
	1:100	22	24	109.1
			<b>Mean %</b>	<b>109</b>

Sample 3 (ID)	Dilution (U/mL)	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
Recovery				

## IMPRECISION

This assay exhibits total imprecision of less than 10% across the assay range. One study, using commercially available human serum based control material generating a total of 20 assays, 2 replicates per assay, over 10 days provided the following data, analyzed via analysis of variance (ANOVA).

Sample	Grand Mean (n=43) (U/mL)	Within Run (%CV)	Between Run (%CV)	Total Imprecision (%CV)
Level 1	23.6	1.7	6.0	6.3
Level 2	74.7	1.3	5.1	5.3
Level 3	740.9	2.1	4.4	4.8
Level 4	2,961.8	2.4	3.3	4.1

## ANALYTICAL SPECIFICITY / INTERFERENCES

Samples containing up to 1,000 mg/dL hemoglobin, 20 mg/dL bilirubin, 1,800 mg/dL triglycerides (triolein) and protein concentrations from 5.0 to 9.0 g/dL protein (human serum albumin) do not affect the concentration of CA 125 antigen assayed.

The following table describes the cross-reactivity of the assay with common chemotherapeutic agents and other potential interferents.

Substance	Concentration Added	Expected (U/mL)	Observed (U/mL)	Mean % Recovery
Doxorubicin	100 µg/mL	15.0	15.4	102.7
Amethopterin	500 µg/mL	15.0	14.9	99.3
Carboplatin	1,000 µg/mL	15.0	15.2	101.3
Cyclophosphamide	1,000 µg/mL	15.0	14.6	97.3
5-fluorouracil	1,000 µg/mL	15.0	14.8	98.7
Cisplatin	2,000 µg/mL	15.0	14.7	98.0
Melphalan	100 µg/mL	15.0	14.6	97.3
Acetaminophen	200 µg/mL	15.0	15.2	101.3
Aspirin	500 µg/mL	15.0	15.0	100.0
Paclitaxel	10 ng/mL	15.0	15.1	100.7

Substance	Concentration Added	Expected (U/mL)	Observed (U/mL)	Mean % Recovery
Biotin	50 ng/mL	15.0	14.4	96.0
Vitamin D <sub>2</sub>	1 U/mL	15.0	14.9	99.3

## ANALYTICAL SENSITIVITY

The lowest detectable level of CA 125 antigen distinguishable from zero (Access OV Monitor Calibrator S0) with 95% confidence is 0.5 U/mL. This value is determined by processing a complete six point calibration curve, controls, and 10 replicates of the zero calibrator in multiple assays. The analytical sensitivity value is calculated from the curve at the point that is two standard deviations from the fitted zero calibrator signal.

## ADDITIONAL INFORMATION



Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

### Symbols Key

Glossary of Symbols is available at [techdocs.beckmancoulter.com](http://techdocs.beckmancoulter.com) (document number C02724)

## REFERENCES

- 1 Davis, et al., Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. *Cancer Res.* 46: 6143-6148, 1986.
- 2 Yancik R: Ovarian Cancer: Age Contrasts in Incidence, Histology, Disease Stage at Diagnosis, and Mortality. *Cancer* 71 (Supp2): 517-523, 1993.
- 3 Omura GA, et al: Long-Term Follow-up and Prognostic Factor Analysis in Advanced Ovarian Carcinoma: The Gynecologic Oncology Group Experience. *J Clin Onco*, 9:7, 1138-1150, 1991.
- 4 Mogensen O: Prognostic Value of CA 125 in Advanced Ovarian cancer, *Gynec Onco*, 44(3): 207-212. 1992.
- 5 Schilthuis MS, et al, Serum CA 125 levels in Epithelial Ovarian Cancer: Relation with Findings at Second-Look Operations and Their Role in the Detection of Tumor Recurrence. *Br J Obstet Gynecol*, 94:202, 1987.
- 6 Kenemans P, et al., CA 125 in Gynecologic Pathology, A Review. *Eur J Obstet Gynecol and Reprod Biol*, 49:115, 1993.
- 7 Berek JS, et al. CA 125 Serum Levels Correlated with Second-Look Operations Among Ovarian Cancer Patients. *Obstet Gynecol*, 67:685, 1986.
- 8 Niloff JM, et al. Predictive Value of CA 125 Antigen Levels in Second-Look Procedures for Ovarian Cancer, *Am J Obstet Gynecol*, 151:981, 1985.
- 9 Fristsche, et al., CA 125 in Ovarian Cancer: Advances and Controversy: *Clin Chem*, 44:1379-1380, 1998.
- 10 NIH Consensus Conference, Ovarian Cancer: Screening, Treatment and Follow-Up. *JAMA* 273:491, 1995.
- 11 Bast RC, et al. Monitoring Human Ovarian Carcinoma with a Combination of CA 125, CA 19-9, and Carcinoembryonic Antigen. *Am J Obstet Gynecol*, 149:553, 1984.
- 12 Approved Guideline - Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests, GP44-A4. 2010. Clinical and Laboratory Standards Institute.
- 13 Cembrowski GS, Carey RN. Laboratory quality management: QC  $\rightleftharpoons$  QA. ASCP Press, Chicago, IL, 1989.
- 14 Kricka L. Interferences in immunoassays - still a threat. *Clin Chem* 2000; 46: 1037-1038.
- 15 Bjerner J, et al. Immunometric assay interference: incidence and prevention. *Clin Chem* 2002; 48: 613-621.

 Beckman Coulter Eurocenter S.A., 22, rue Juste-Olivier. Case Postale 1044, CH - 1260  
Nyon 1, Switzerland Tel: +41 (0)22 365 36 11  
 Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.